56 articles
NVIDIA is turning BioNeMo into shared AI infrastructure for drug discovery, cementing partnerships with Thermo Fisher and Eli Lilly as specialized model platforms launch on top of it. Novo Nordisk shuttered its internal cell therapy unit to license the program to AI firm Cellular Intelligence, while MindWalk moves to defend its foundational biotech patents.
NVIDIA's BioNeMo platform has secured co-innovation lab agreements with Eli Lilly and Thermo Fisher, consolidating its position as pharmaceutical AI infrastructure. Novo Nordisk stock climbed 24.9% last month after licensing its Parkinson's cell therapy to AI-native biotech Cellular Intelligence. FDA Fast Track designation for the program reduces a key regulatory barrier for AI-assisted drug pipelines.
Novo Nordisk has licensed its Parkinson's cell therapy program to AI-native partner Cellular Intelligence and closed its internal unit, signaling that big pharma is choosing to outsource AI-driven discovery rather than build in-house. NVIDIA's BioNeMo ecosystem and a wave of biological foundation models are driving the shift from experimental AI tools to operational drug discovery infrastructure. NVO shares have climbed 25% over the past month as markets price in the combined GLP-1 and AI thesis
GuideAI Health Corp. completed a business combination on June 16, 2026, replacing its entire board and management while securing Cboe Canada conditional listing approval the same day. A brokered private placement of $5.15M in subscription receipts preceded the listing. The transaction fits a pattern of AI-branded reverse mergers raising capital without disclosed AI revenue.
NVIDIA has become the central AI infrastructure layer for biotech, with its BioNeMo platform underpinning foundation models at Terray Therapeutics and Apheris while anchoring partnerships with Eli Lilly and Thermo Fisher. Novo Nordisk's decision to close its internal cell therapy unit and license Parkinson's assets to AI-native Cellular Intelligence signals a broader shift toward externalized, platform-driven drug development. A wave of new AI biotech platforms — Boltz, Owkin, Basecamp EDEN, Edi
GuideAI Health Corp.'s Cboe Canada listing remains conditional, with failure to satisfy exchange requirements potentially forcing return of all subscription receipt proceeds and unwinding its post-combination capital structure. The healthcare AI company is developing a clinical intelligence platform for vascular and cardiovascular disease detection. A listing failure would cut off public capital access at a critical development stage.
NVIDIA's BioNeMo platform is becoming the central AI infrastructure layer connecting pharmaceutical giants—Novo Nordisk, Lilly, and Thermo Fisher—with AI-native drug discovery. Novo Nordisk posted a Q1 2026 earnings beat with a 24.9% 30-day stock surge, while simultaneously outsourcing Parkinson's programs to AI partner Cellular Intelligence. A maturing ecosystem of specialized biotech AI platforms signals the picks-and-shovels layer of pharma AI is consolidating fast.
NVIDIA's BioNeMo platform has formalized AI-driven drug discovery at enterprise scale with co-innovation partnerships involving Eli Lilly and Thermo Fisher. Novo Nordisk restructured its portfolio by licensing cell therapy to AI-native spinout Cellular Intelligence while closing its internal unit to concentrate on GLP-1. A wave of commercial foundation model launches signals AI adoption in biotech has moved from experimentation to operational lock-in.
Eli Lilly has broken its own acquisition record, surpassing $20 billion in deals in 2026 alone — including Kelonia Therapeutics ($7B), Centessa Pharmaceuticals ($7.8B), and three vaccine developers ($3.8B). The pace reflects a strategic calculation: AI-accelerated drug discovery is making early-stage biotech assets cheaper to evaluate and integrate, shifting the math away from internal R&D.
NVIDIA has embedded its BioNeMo platform into biopharma R&D pipelines through partnerships with Thermo Fisher, Eli Lilly, and a cohort of AI-bio startups. Novo Nordisk surged 24.9% over 30 days after exiting internal cell therapy in favor of AI-enabled licensing. A proliferation of competing foundation model platforms signals the sector has entered a full infrastructure buildout phase.
GRAIL's Galleri multi-cancer blood test failed to achieve a statistically significant reduction in late-stage cancer detection in its three-year NHS trial, reported February 1, 2026. The miss put FDA approval in doubt and sent GRAIL shares down more than 20%. The company is now growing Galleri sales primarily through out-of-pocket purchases rather than insurer reimbursement.
NVIDIA's BioNeMo platform has secured partnerships with Eli Lilly and Thermo Fisher, positioning it as the shared backbone of AI-driven drug discovery. Five competing platforms — Boltz Lab, Edison Kosmos, OwkinZero, Basecamp Research EDEN, and Natera — are challenging across distinct pipeline segments. Novo Nordisk's 24.9% stock surge and pivot to AI-native partnerships signal that pharma's infrastructure bet is now being priced by markets.
NVIDIA's BioNeMo platform has anchored partnerships with Eli Lilly and Thermo Fisher, emerging as the de facto AI infrastructure layer for pharmaceutical drug discovery. Novo Nordisk closed its internal cell therapy unit and licensed the program to AI-native startup Cellular Intelligence — then saw its stock climb 25% in a month. Investors are reading the outsourcing pivot as value-creative, not a retreat.
NVIDIA's BioNeMo platform is becoming the foundational compute layer for AI-driven pharmaceutical discovery, with Novo Nordisk and Eli Lilly restructuring R&D around AI-native workflows. Novo Nordisk posted strong Q1 2026 earnings and a 25% stock surge after closing its internal cell therapy unit and outsourcing Parkinson's development to AI-platform company Cellular Intelligence. A concurrent wave of platform launches — Basecamp Research EDEN, Boltz Lab, Owkin OwkinZero, Edison Scientific Kosmo
NVIDIA's BioNeMo platform has attracted partnerships from Eli Lilly and Thermo Fisher, establishing itself as central AI infrastructure for drug discovery. Five competing platforms launched concurrently, signaling rapid commoditization of biotech AI tooling. Novo Nordisk's +24.9% 30-day gain and decision to license its Parkinson's program to an AI-native partner illustrates how large pharma is restructuring around this infrastructure layer.
RadNet posted Q1 2026 revenue growth of 22.1% and adjusted EBITDA growth of 36.3% year-over-year, with EBITDA outpacing revenue — a signal of operational leverage. AI scheduling platform TechLive and diagnostic AI tool DeepHealth are cited as key contributors. MRI same-center volume grew 10.1%, well above industry baseline, while imaging center margins improved 188 basis points.
Novo Nordisk's stock surged 24.9% after closing its cell therapy unit and licensing its Parkinson's program to AI-native Cellular Intelligence. NVIDIA's BioNeMo platform has become the central infrastructure layer connecting pharma incumbents to AI-first drug discovery firms. A concurrent wave of specialized biological AI models from Basecamp Research, Owkin, and others signals competitive differentiation is moving up the stack.
Paradigm Health has gone live with its Study Conduct platform simultaneously supporting Phase 1b and Phase 2 clinical trials for Amgen and AstraZeneca. Early operational failures—including EHR integration outages, data ingestion errors, and algorithmic misclassification—risk invalidating trial data and triggering liability from both sponsors. The concurrent multi-sponsor launch amplifies exposure at a moment when FDA trust in the platform is still being established.
NVIDIA secured simultaneous BioNeMo platform agreements with Eli Lilly and Thermo Fisher in January 2026, anchoring itself as foundational AI infrastructure for pharmaceutical research. The dual partnerships triggered a wave of AI foundation model launches from five specialized biotech firms. The dynamic mirrors cloud computing's consolidation: dominant infrastructure enabling an ecosystem of specialized applications.
Amgen restructured its R&D leadership, placing James Bradner over a combined 'R&D, AI and Data' function alongside a new CTO appointment. At AACR 2026, Rakovina Therapeutics and Revolution Medicines presented generative AI-designed programs targeting CNS-penetrant oncology and KRAS G12 mutations. Across Big Pharma and AI-native biotechs, generative AI is solving structural drug design failures — not merely accelerating legacy workflows.